New drug cocktail targets Hard-to-Treat gut cancers
NCT ID NCT05039177
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new cancer drug called ERAS-007, given by mouth, together with other targeted therapies in 101 people with advanced colorectal or pancreatic cancers that have certain gene changes. The main goals were to check safety, find the best dose, and see how the drugs work in the body. The trial is now complete, and results will help guide future studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ERAS-007 (a targeted cancer drug taken by mouth) combined with other drugs (encorafenib, cetuximab, or palbociclib)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced colorectal or pancreatic cancers that have specific genetic mutations.
What could go wrong
This is an early-phase trial focused on safety and dosing, not yet on effectiveness. The combination may cause side effects or fail to shrink tumors. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope
Duarte, California, 91010, United States
-
Duke Cancer Institute
Durham, North Carolina, 27710, United States
-
Henry Ford Cancer Institute
Detroit, Michigan, 48202, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02215, United States
-
Sarah Cannon Research Institute (Tennessee Oncology)
Nashville, Tennessee, 37203, United States
-
Stephenson Cancer Center
Oklahoma City, Oklahoma, 73104, United States
-
The Johns Hopkins Hospital
Baltimore, Maryland, 21287, United States
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
UCSF Mount Zion Medical Ctr
San Francisco, California, 94158, United States
-
University of Alabama at Birmingham (O'Neal Comprehensive Cancer Center)
Birmingham, Alabama, 35233, United States
-
University of California Irvine College of Medicine
Orange, California, 92868, United States
-
University of Washington - Seattle Cancer Care Alliance
Seattle, Washington, 98109, United States
-
Virginia Cancer Specialists
Fairfax, Virginia, 22031, United States
-
Washington University (Siteman Cancer Center)
St Louis, Missouri, 63110, United States